Cécile Chartier
Director/Board Member at CELLECTIS S.A.
Profile
Cécile Chartier is currently working as a Director at Cellectis SA and as the Chief Scientific Officer at NextVivo, Inc. She holds a doctorate degree from Universite Louis Pasteur Strasbourg I.
Cécile Chartier active positions
Companies | Position | Start |
---|---|---|
CELLECTIS S.A. | Director/Board Member | 26/06/2023 |
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Chief Tech/Sci/R&D Officer | - |
Training of Cécile Chartier
Universite Louis Pasteur Strasbourg I | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
CELLECTIS S.A. | Health Technology |
Private companies | 1 |
---|---|
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services NextVivo, Inc. is a biotech company based in California that is focused on developing an immune organoid technology platform to accelerate the development of safer and more effective therapies. The American company's mission is to generate and test immune-competent human-derived models that can be used to develop cell and antibody therapies and test immune-modulating drug candidates for a range of diseases, including cancer, infection, and autoimmune disorders. The company was co-founded by Dr. Mark Davis and Dr. Calvin Kuo from Stanford University, and by Dr. Adam Margolin, former chair and professor of genetics and genomic science and senior associate dean. Dr. Adam Margolin has been the CEO since incorporation. | Technology Services |
- Stock Market
- Insiders
- Cécile Chartier